XBIO
Xenetic Biosciences, Inc.
Price Chart
Latest Quote
$2.25
Current Price| Previous Close | $2.22 |
| Open | $2.27 |
| Day High | $2.28 |
| Day Low | $2.25 |
| Volume | 2,532 |
Stock Information
| Shares Outstanding | 2.29M |
| Cash Equivalents | $4.12M |
| Revenue | $2.86M |
| Net Income | $-3.16M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $5.15M |
| EPS (TTM) | $-2.04 |
| Exchange | NCM |
đ Custom Metrics & Score
Score: 17/42| Debt to Equity | 0.15 |
| Debt to Earnings | -0.23 |
| Current Ratio | 7.37 |
| Quick Ratio | 6.89 |
| Avg Revenue Growth | 28.85% |
| Profit Margin | -158.39% |
| Return on Equity | -65.93% |
| Avg FCF Growth | -10.13% |
| FCF Yield | -54.66% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $2.25 | 6,200 |
| 2026-01-30 | $2.22 | 15,600 |
| 2026-01-29 | $2.33 | 20,900 |
| 2026-01-28 | $2.49 | 7,300 |
| 2026-01-27 | $2.55 | 44,200 |
| 2026-01-26 | $2.55 | 15,500 |
| 2026-01-23 | $2.65 | 30,700 |
| 2026-01-22 | $2.77 | 42,600 |
| 2026-01-21 | $2.42 | 27,900 |
| 2026-01-20 | $2.50 | 57,000 |
| 2026-01-16 | $2.42 | 81,700 |
| 2026-01-15 | $2.28 | 22,900 |
| 2026-01-14 | $2.21 | 18,400 |
| 2026-01-13 | $2.21 | 32,900 |
| 2026-01-12 | $2.30 | 19,000 |
| 2026-01-09 | $2.21 | 7,800 |
| 2026-01-08 | $2.18 | 19,500 |
| 2026-01-07 | $2.17 | 7,300 |
| 2026-01-06 | $2.11 | 22,200 |
| 2026-01-05 | $2.19 | 10,500 |
About Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop DNase technology for the treatment of immunotherapies. The company offers under XDNASE, XCART, OncoHist, PolyXen, ErepoXen, and ImuXen trandemarks. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
đ° Latest News
Xenetic Biosciences: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-12T22:43:56ZAmneal Pharmaceuticals (AMRX) Beats Q3 Earnings and Revenue Estimates
Zacks âĸ 2025-10-30T11:15:01Z
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates
Zacks âĸ 2025-08-12T22:25:01Z
Xenetic Biosciences: Q2 Earnings Snapshot
Associated Press Finance âĸ 2025-08-12T21:26:26ZXenetic Biosciences: Q1 Earnings Snapshot
Associated Press Finance âĸ 2025-05-13T21:10:38ZXenetic Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Simply Wall St. âĸ 2025-03-20T11:00:57Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $2,500,284 | $2,539,986 | $1,706,925 | $1,160,692 |
| Operating Revenue | $2,500,284 | $2,539,986 | $1,706,925 | $1,160,692 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Expenses | $6,704,712 | $7,055,701 | $8,424,833 | $6,907,457 |
| Other Income Expense | $-5,708 | $25,380 | $-1,597 | $1,119 |
| Other Non Operating Income Expenses | $-5,708 | $25,380 | $-1,597 | $1,119 |
| Net Non Operating Interest Income Expense | $249,861 | $355,757 | $167,152 | $100,467 |
| Operating Expense | $6,704,712 | $7,055,701 | $8,424,833 | $6,907,457 |
| General And Administrative Expense | $3,416,380 | $3,560,936 | $3,653,999 | $3,743,972 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-3,960,275 | $-4,134,578 | $-6,552,353 | $-5,645,179 |
| Net Interest Income | $249,861 | $355,757 | $167,152 | $100,467 |
| Interest Income | $249,861 | $355,757 | $167,152 | $100,467 |
| Normalized Income | $-3,960,275 | $-4,134,578 | $-6,552,353 | $-5,645,179 |
| Net Income From Continuing And Discontinued Operation | $-3,960,275 | $-4,134,578 | $-6,552,353 | $-5,645,179 |
| Total Operating Income As Reported | $-4,204,428 | $-4,515,715 | $-6,717,908 | $-5,746,765 |
| Net Income Common Stockholders | $-3,960,275 | $-4,134,578 | $-6,552,353 | $-5,645,179 |
| Net Income | $-3,960,275 | $-4,134,578 | $-6,552,353 | $-5,645,179 |
| Net Income Including Noncontrolling Interests | $-3,960,275 | $-4,134,578 | $-6,552,353 | $-5,645,179 |
| Net Income Continuous Operations | $-3,960,275 | $-4,134,578 | $-6,552,353 | $-5,645,179 |
| Pretax Income | $-3,960,275 | $-4,134,578 | $-6,552,353 | $-5,645,179 |
| Interest Income Non Operating | $249,861 | $355,757 | $167,152 | $100,467 |
| Operating Income | $-4,204,428 | $-4,515,715 | $-6,717,908 | $-5,746,765 |
| Special Income Charges | - | - | - | $0 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-2.57 | $-2.71 | $-4.61 | $-5.50 |
| Basic EPS | $-2.57 | $-2.71 | $-4.61 | $-5.50 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-4,204,428 | $-4,515,715 | $-6,690,865 | $-5,711,283 |
| EBITDA (Bullshit earnings) | $-4,204,428 | $-4,515,715 | $-6,690,865 | $-5,711,283 |
| EBIT | $-4,204,428 | $-4,515,715 | $-6,717,908 | $-5,746,765 |
| Diluted Average Shares | $1,541,339 | $1,528,210 | $1,422,443 | $1,027,940 |
| Basic Average Shares | $1,541,339 | $1,528,210 | $1,422,443 | $1,027,940 |
| Diluted NI Availto Com Stockholders | $-3,960,275 | $-4,134,578 | $-6,552,353 | $-5,645,179 |
| Research And Development | $3,288,332 | $3,494,765 | $4,770,834 | $3,163,485 |
| Selling General And Administration | $3,416,380 | $3,560,936 | $3,653,999 | $3,743,972 |
| Other Gand A | $3,416,380 | $3,560,936 | $3,653,999 | $3,743,972 |
| Reconciled Depreciation | - | $0 | $27,043 | $35,482 |
| Total Unusual Items | - | - | - | $0 |
| Total Unusual Items Excluding Goodwill | - | - | - | $0 |
| Tax Provision | - | - | - | $0 |
| Impairment Of Capital Assets | - | - | - | $0 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $6,007,180 | $9,795,641 | $13,647,134 | $18,394,257 |
| Total Assets | $6,901,443 | $10,605,226 | $14,720,290 | $19,815,360 |
| Total Non Current Assets | $313,921 | $1,018,352 | $1,066,931 | $1,091,931 |
| Other Non Current Assets | $313,921 | $1,018,352 | $1,066,931 | $1,091,931 |
| Current Assets | $6,587,522 | $9,586,874 | $13,653,359 | $18,723,429 |
| Other Current Assets | $421,954 | $603,828 | $556,094 | - |
| Cash Cash Equivalents And Short Term Investments | $6,165,568 | $8,983,046 | $13,097,265 | $18,244,030 |
| Cash And Cash Equivalents | $6,165,568 | $8,983,046 | $13,097,265 | $18,244,030 |
| Cash Financial | $6,165,568 | $8,983,046 | $13,097,265 | $18,244,030 |
| Prepaid Assets | - | - | $556,094 | $479,399 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $894,263 | $809,585 | $1,073,156 | $1,421,103 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $894,263 | $809,585 | $1,073,156 | $1,421,103 |
| Other Current Liabilities | $34,203 | $48,256 | $39,949 | $66,201 |
| Payables And Accrued Expenses | $860,060 | $761,329 | $1,033,207 | $1,354,902 |
| Payables | $283,615 | $240,832 | $287,360 | $362,470 |
| Accounts Payable | $283,615 | $240,832 | $287,360 | $362,470 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $6,005,376 | $9,793,837 | $13,644,360 | $18,391,483 |
| Preferred Stock Equity | $1,804 | $1,804 | $2,774 | $2,774 |
| Total Equity Gross Minority Interest | $6,007,180 | $9,795,641 | $13,647,134 | $18,394,257 |
| Stockholders Equity | $6,007,180 | $9,795,641 | $13,647,134 | $18,394,257 |
| Gains Losses Not Affecting Retained Earnings | $253,734 | $253,734 | $253,734 | $253,734 |
| Other Equity Adjustments | $253,734 | $253,734 | $253,734 | $253,734 |
| Retained Earnings | $-197,194,471 | $-193,234,196 | $-189,099,618 | $-182,547,265 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Treasury Shares Number | $2,701 | $2,701 | $2,699 | $2,699 |
| Ordinary Shares Number | $1,542,139 | $1,540,684 | $1,516,659 | $1,343,961 |
| Share Issued | $1,544,840 | $1,543,385 | $1,519,358 | $1,346,660 |
| Tangible Book Value | $6,005,376 | $9,793,837 | $13,644,360 | $18,391,483 |
| Invested Capital | $6,005,376 | $9,793,837 | $13,644,360 | $18,391,483 |
| Working Capital | $5,693,259 | $8,777,289 | $12,580,203 | $17,302,326 |
| Total Capitalization | $6,007,180 | $9,795,641 | $13,647,134 | $18,394,257 |
| Treasury Stock | $5,281,180 | $5,281,180 | $5,281,180 | $5,281,180 |
| Additional Paid In Capital | $208,225,748 | $208,053,935 | $207,769,904 | $205,952,729 |
| Capital Stock | $3,349 | $3,348 | $4,294 | $16,239 |
| Common Stock | $1,545 | $1,544 | $1,520 | $13,465 |
| Preferred Stock | $1,804 | $1,804 | $2,774 | $2,774 |
| Current Accrued Expenses | $576,445 | $520,497 | $745,847 | $992,432 |
| Net PPE | - | - | - | $0 |
| Accumulated Depreciation | - | - | - | $-50,243 |
| Gross PPE | - | - | - | $50,243 |
| Machinery Furniture Equipment | - | - | - | $50,243 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-2,817,478 | $-4,114,219 | $-5,146,765 | $-4,738,067 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-2,817,478 | $-4,114,219 | $-4,646,765 | $-4,738,067 |
| Cash Flow From Continuing Operating Activities | $-2,817,478 | $-4,114,219 | $-4,646,765 | $-4,738,067 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Investing Cash Flow | - | $0 | $-500,000 | $0 |
| Cash Flow From Continuing Investing Activities | - | $0 | $-500,000 | $0 |
| Capital Expenditure | - | - | $-500,000 | - |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | - | - | $0 | $11,450,866 |
| Financing Cash Flow | - | - | $0 | $11,454,545 |
| Cash Flow From Continuing Financing Activities | - | - | $0 | $11,454,545 |
| Net Common Stock Issuance | - | - | $0 | $11,450,866 |
| Common Stock Issuance | - | - | $0 | $11,450,866 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $6,165,568 | $8,983,046 | $13,097,265 | $18,244,030 |
| Beginning Cash Position | $8,983,046 | $13,097,265 | $18,244,030 | $11,527,552 |
| Changes In Cash | $-2,817,478 | $-4,114,219 | $-5,146,765 | $6,716,478 |
| Change In Working Capital | $970,983 | $-262,726 | $-426,685 | $461,193 |
| Change In Other Current Assets | $704,431 | $48,579 | $25,000 | $-281,946 |
| Change In Payables And Accrued Expense | $84,678 | $-263,571 | $-347,947 | $457,132 |
| Change In Payable | $84,678 | $-263,571 | $-347,947 | $457,132 |
| Change In Account Payable | $84,678 | $-263,571 | $-347,947 | $457,132 |
| Change In Prepaid Assets | $181,874 | $-47,734 | $-103,738 | $286,007 |
| Stock Based Compensation | $171,814 | $283,085 | $511,480 | $410,437 |
| Net Income From Continuing Operations | $-3,960,275 | $-4,134,578 | $-6,552,353 | $-5,645,179 |
| Net Intangibles Purchase And Sale | - | $0 | $-500,000 | $0 |
| Purchase Of Intangibles | - | $0 | $-500,000 | $0 |
| Depreciation Amortization Depletion | - | $0 | $27,043 | $35,482 |
| Depreciation And Amortization | - | $0 | $27,043 | $35,482 |
| Depreciation | - | $0 | $27,043 | $35,482 |
| Proceeds From Stock Option Exercised | - | - | $0 | $3,679 |
| Other Non Cash Items | - | - | $1,793,750 | - |
| Asset Impairment Charge | - | - | - | $0 |
| Deferred Tax | - | - | - | $0 |
| Deferred Income Tax | - | - | - | $0 |